Sign in

CIK 0001737953

  • Non-accelerated filer
  • Smaller reporting company

Replimune Group, Inc.

Sign in to watch
Ticker
REPL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Mar 31
Incorporated
DE
Entity type
Operating
EIN
822082553
Phone
+1 781-222-9600
Business address
500 UNICORN PARK, WOBURN, MA, 01801
  1. 4 Grant or award Chief Medical Officer acquired 20,500 shares (grant or award)
  2. 4 Grant or award Chief Financial Officer acquired 46,035 shares (grant or award)
  3. 4 Grant or award President & Chief R&D Officer acquired 76,865 shares (grant or award)
  4. 4 Grant or award Chief Executive Officer acquired 85,415 shares (grant or award)
  5. 4 Grant or award Chief Operating Officer acquired 39,285 shares (grant or award)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market sale Chief Operating Officer sold 30,000 shares at an average $33.54 ($1,006,106)
  16. 4 Open-market sale Chief Operating Officer sold 30,000 shares at an average $36.32 ($1,089,537)
  17. 4 Open-market sale 10% owner sold 5,249 shares at $45.00 ($236,205)
  18. 4 Open-market sale Director sold 5,558 shares at $46.14 ($256,446)
  19. 4 Open-market sale Director sold 30,350 shares at an average $45.42 ($1,378,444)
  20. 4 Open-market sale President & Chief R&D Officer sold 60,000 shares at an average $44.43 ($2,665,973)

Page 10 of 16 · 316 filings